{
  "chapter": "Endocrine Surgery-Breast-Ii",
  "questions": [
    {
      "q_no": 1,
      "question": "Which of the following are indications for adjuvant chemotherapy in breast cancer? Post-surgery eradication of microscopic residual disease in high-risk patients Inflammatory breast cancer. HER2-positive breast cancer in combination with HER2-targeted therapy Triple-negative breast cancer Enabling breast-conserving surgery by reducing tumor size.",
      "options": {
        "A": "1, 3, and 5 are correct",
        "B": "2, 3, and 5 are correct",
        "C": "2, 4, and 5 are correct",
        "D": "1, 3, and 4 are correct"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) 1, 3, and 4 are correct. Explanation: Indications for Chemotherapy in Breast Cancer : Neoadjuvant Therapy Treatment given before surgery to shrink tumors and make surgery easier. Tumor downstaging before surgery, especially for large or near chest wall/skin tumors. Adjuvant Therapy Treatment given after surgery to eradicate microscopic residual disease and reduce the risk of recurrence. Post-surgery eradication of microscopic residual disease in high-risk patients. Node-positive disease. High-risk node-negative disease based on tumor characteristics. Tumors greater than 2 cm with additional risk factors. High-grade tumors. HER2-positive breast cancer in combination with HER2-targeted therapy. Triple-negative breast cancer. Genomic assays indicating benefit of chemotherapy in early-stage breast cancer. Palliative Therapy Treatment aimed at relieving symptoms and improving the quality of life in advanced cancer cases. Drugs Drugs Use Anthracyclines Doxorubicin Epirubicin Neoadjuvant and adjuvant therapy; broad efficacy Taxanes Paclitaxel Docetaxel Adjuvant therapy and metastatic disease Alkylating Agents Cyclophosphamide Ifosfamide Combination regimens for early and metastatic cancer Antimetabolites 5-Fluorouracil Methotrexate Often combined in regimens for early-stage cancer Platinum-Based Agents Carboplatin Cisplatin Triple-negative breast cancer, BRCA mutations Regimens AC (Doxorubicin and Cyclophosphamide): Use: Early-stage and advanced breast cancer. Often used as a neoadjuvant or adjuvant treatment. TAC (Docetaxel, Doxorubicin, and Cyclophosphamide): Use: Early-stage breast cancer. CAF (Cyclophosphamide, Doxorubicin, and 5-Fluorouracil): Use: Early-stage breast cancer. CMF (Cyclophosphamide, Methotrexate, and 5-Fluorouracil): Use: Early-stage breast cancer, especially where anthracyclines are contraindicated.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 2,
      "question": "A 28-year-old lactating mother presents with fever, breast pain, swelling, and a tender, erythematous area on her left breast. Ultrasonography confirms the presence of a pus-filled cavity. What would be the initial treatment in this scenario?",
      "options": {
        "A": "Close Observation",
        "B": "Antibiotics and breast emptying",
        "C": "Hormonal therapy",
        "D": "Surgical excision"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Antibiotics and breast emptying Explanation: The given clinical history of a lactating mother with painful, tender breasts with ultrasound findings of pus-filled cavity is suggestive of lactational abscess. The preferred treatment would be antibiotics and breast emptying. Breast Abscess Definition Pus-filled cavity within breast tissue. Types Lactational Abscess : Associated with breastfeeding. Non-Lactational Abscess: Occurs in non-lactating women, e.g., periductal mastitis. Causes and Risk Factors Lactation: Incidence: 3% to 20% in lactating mothers. Common pathogen: Staphylococcus aureus (methicillin-resistant strains in hospital settings). Entry points: Cracked/retracted nipple, blocked lactiferous ducts. Non-Lactation: Often in nulliparous women or post-lactation. Conditions: Periductal mastitis, idiopathic granulomatous mastitis, tubercular mastitis . Smoking and diabetes as risk factors. Signs and symptoms Fever, leukocytosis, erythema, pain and tenderness, swelling, malaise, difficulty feeding, enlarged and tender axillary nodes Diagnosis Ultrasonography: Detects cellulitis, liquefaction necrosis. Confirms abscess size, location, and loculation. Treatment Lactational Mastitis: Antibiotics: Anti-staphylococcal (e.g., cloxacillin, flucloxacillin, erythromycin). Breast emptying: Frequent breastfeeding or pumping. Support: Breast support garment, cold compresses, analgesia. Drainage: Ultrasound-guided preferred over surgical incision. Follow-up: Regular clinical and ultrasonographic reviews, culture-based antibiotic modification. Non-Lactational Mastitis: Broad-spectrum antibiotics for subareolar infections. Needle aspiration for abscess drainage. Major milk duct excision for complications like sepsis or fistula. Reference: Sabiston Textbook of Surgery, 21st Edition, Pages 826,827 Bailey & Love's Short Practice of Surgery, 28th Edition, Pages 927,928 Schwartz's Principles of Surgery, 11th Edition, Pages 550-553, 601, 602",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 3,
      "question": "A 35-year-old lactating woman presents with a rapidly progressing, painful, and warm swelling involving her entire left breast. She was diagnosed with inflammatory breast cancer. Which of the following statements are correct regarding her condition?",
      "options": {
        "A": "The prognosis is bad",
        "B": "Stage III B carcinoma (T4d)",
        "C": "Can be mistaken for acute mastitis",
        "D": "All are true"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) All are true Explanation: Inflammatory breast cancer: Characteristic Details Nature Most aggressive Rapidly progressive Worst prognosis Short duration Rapidly metastasizes to chest wall, bone, and lungs Always stage III B carcinoma (T4d) Common in lactating women or pregnancy Synonyms Lactating carcinoma/Mastitis carcinomatosis Clinical Presentation Diffuse, painful, warm, often involving whole breast tissue Peau d'orange appearance More than 1/3rd of the skin over the breast is involved; often extends to the skin of the chest wall Diffuse lymphoedema Diagnosis Clinical diagnosis Histology Ductal or lobular invasive type with cancer cells in dermal lymphatics Confirmation Tests FNAC (Fine Needle Aspiration Cytology) Punch biopsy is ideal and better Treatment External radiotherapy and chemotherapy Salvage surgery whenever possible Differential Diagnosis Acute mastitis (total count is increased in acute mastitis and normal in inflammatory breast cancer) Reference: SRB's Manual of Surgery, 6th Edition, Page 525",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxsurgery/Endocrine_Surgery-Breast-Ii_Q3_q.jpg",
      "explanation_image": null,
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 4,
      "question": "A 45-year-old woman with a family history of breast cancer undergoes genetic testing and is found to have a BRCA1 mutation. What are the implications of this mutation regarding her cancer risks and potential associated cancers? colon and prostate cancers.",
      "options": {
        "A": "Increased risk of breast cancer with well-differentiated hormone receptor-positive tumors.",
        "B": "Increased risk of breast cancer, typically high-grade and triple-negative, along with higher risks of",
        "C": "Increased risk of breast cancer and higher risk of endometrial cancer.",
        "D": "Increased risk of ovarian cancer with no significant increase in breast cancer risk."
      },
      "correct_answer": "B",
      "explanation": "with higher risks of colon and prostate cancers. Correct Answer: B) Increased risk of breast cancer, typically high-grade and triple-negative, along with higher risks of colon and prostate cancers. Explanation: BRCA1 mutations are associated with high-grade, triple-negative breast cancers and increased risks of colon and prostate cancers. Category BRCA1 BRCA2 Prevalence General Population: Rare (1 in 1000) General Population: Rare (1 in 1000) Chromosome Location Chromosome 17q21 Chromosome 13q12 Inheritance Pattern Autosomal dominant : 50% chance of inheritance from an affected parent Autosomal dominant : 50% chance of inheritance from an affected parent Cancer Risks Breast Cancer: 60-70% lifetime risk, up to 85% in some families Male Breast Cancer: Not increased Breast Cancer: Slightly lower risk, nearing 85% Male Breast Cancer: Increased risk (6%) Ovarian Cancer Up to 40% lifetime risk 20-30% lifetime risk Breast Cancer Characteristics High grade, hormone receptor-negative Often triple-negative (ER-negative, PR-negative, HER2-negative) Basal phenotype Typically invasive ductal carcinomas More likely hormone receptor-positive (Option A) Well-differentiated Associated Cancers Increased risk of colon and prostate cancers Broader spectrum: prostate, colon, pancreatic, gallbladder, bile duct, stomach cancers and melanoma Penetrance Inheriting a mutation does not guarantee cancer but significantly increases risk Inheriting a mutation does not guarantee cancer but significantly increases risk Increased risk of breast cancer and higher risk of endometrial cancer (Option C): Mutations in genes like PTEN (associated with Cowden syndrome) increase the risk of both breast and endometrial cancers. BRCA mutations are not specifically linked to a higher risk of endometrial cancer. Increased risk of ovarian cancer with no significant increase in breast cancer risk (Option D): BRCA1 mutations significantly increase both breast and ovarian cancer risks. Reference: Sabiston Textbook of Surgery, 21st Edition, Pages 822-824 Bailey & Love's Short Practice of Surgery, 28th Edition, Pages 931, 935, 940, 941 Schwartz's Principles of Surgery, 11th Edition, Pages 558, 559",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 5,
      "question": "A 35-year-old woman presents with cyclical breast pain and palpable lumps in her breasts. She reports that the pain increases just before her menstrual period. Physical examination reveals dense breast tissue without any nipple discharge or skin involvement. What is the most likely diagnosis?",
      "options": {
        "A": "Mucinous carcinoma",
        "B": "Fibrocystic Changes",
        "C": "Medullary Carcinoma",
        "D": "Ductal carcinoma"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Fibrocystic Changes Explanation: The history of cyclical breast pain with palpable lumps is suggestive of fibrocystic changes of the breast. Fibrocystic changes Terminology Fibrocystic disease is outdated Current term: Fibrocystic changes Causes Believed to result from an exaggerated response to hormonal fluctuations , particularly estrogen. Involves hypertrophy and altered morphology rather than hyperplasia. Symptoms Common: Breast pain (mastalgia) , either cyclical (linked to menstrual cycle) or non cyclical . Breast may feel lumpy or dense . Palpable cysts may develop. Diagnosis Patient history: Age, menstrual history, previous breast biopsies. Physical examination: Visual inspection, palpation of breast tissue and lymph nodes Imaging tests: Mammography : Detects dense tissue or cysts. Ultrasound : Differentiates cysts from solid masses. Biopsy: To rule out malignancy or evaluate suspicious findings. Treatment No treatment is needed for mild symptoms. Symptomatic relief Cyst aspiration : Draining fluid from large or painful cysts. Hormonal therapy : Medications like danocrine, lupron, or tamoxifen in some cases (not typically first-line treatment due to potential side effects). Special Considerations Normally benign Some histological findings within fibrocystic changes, such as atypical ductal hyperplasia (ADH), increase the future risk of breast cancer. Mucinous carcinoma (Option A): A rare type of breast cancer characterized by the presence of mucus-producing cancer cells. It presents as a painless lump rather than cyclical pain and multiple cysts. Medullary Carcinoma (Option C): A subtype of invasive ductal carcinoma that presents as a well-defined, often rapidly growing mass . It does not present with cyclical pain or multiple cysts. Ductal carcinoma (Option D): The most common type of breast cancer that usually presents as a single, firm, painless lump . It does not typically cause cyclical breast pain or multiple cysts. Reference: Sabiston Textbook of Surgery, 21st Edition, Pages 813, 814 Bailey & Love's Short Practice of Surgery, 28th Edition, Pages 914-919",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 6,
      "question": "A 35-year-old woman presents with a tender, thrombosed subcutaneous cord on her right breast, which becomes more pronounced when she raises her arm. She reports no recent trauma or infections. What is the most likely diagnosis?",
      "options": {
        "A": "Ductal carcinoma in situ",
        "B": "Mondor's Disease",
        "C": "Mastitis",
        "D": "Fibrocystic Changes"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Mondor's Disease Explanation: Mondor’s disease Thrombophlebitis of superficial veins in the breast and anterior chest wall. Benign , self-limiting condition, not indicative of cancer. Cause Unknown; can be due to injury or infection. Affected Veins: Lateral thoracic, thoracoepigastric, and superficial epigastric veins. Clinical features Tender, thrombosed subcutaneous cord attached to the skin ( string phlebitis ) Narrow, shallow subcutaneous groove appears on arm Raise Treatment Limit arm movement Anti-inflammatory medications Warm compresses Biopsy- if diagnosis is uncertain or a mass is present near the cord. Prognosis Symptoms usually resolve in 4 to 6 weeks without recurrence or complications. Ductal carcinoma in situ (Option A): Typically presents as a non-palpable lesion found on mammography; less likely to present with a thrombosed cord. Mastitis (Option C): Usually presents with pain, swelling, and redness. Fibrocystic Changes (Option D): Typically involves lumpy, dense breast tissue and cyclic breast pain.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 7,
      "question": "A 20-year-old woman presents with a painless, firm, mobile lump in her breast. On physical examination, the lump is approximately 1 cm in diameter, firm, well-circumscribed, and freely mobile. Ultrasound confirms a well-defined, solid, homogeneous mass with smooth margins and no signs of calcifications. What is the most likely diagnosis and management plan?",
      "options": {
        "A": "Cyst; surgical excision.",
        "B": "Fibroadenoma; conservative management with regular monitoring.",
        "C": "Giant fibroadenoma; immediate surgical removal.",
        "D": "Inflammatory carcinoma; urgent biopsy and treatment."
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Fibroadenoma; conservative management with regular monitoring. Explanation: Fibroadenoma Definition Benign tumors arising from the proliferation of glandular tissue in the breast Prevalence Most common in women aged 15-25 years Aetiology Believed to be influenced by hormonal fluctuations during reproductive years Clinical Presentation Painless, firm, rubbery, and mobile lumps Described as feeling like a \"marble in the breast\" Diagnosis Triple Assessment : Clinical examination, radiological imaging (ultrasound), tissue sampling (core-needle biopsy) Ultrasound: Helps distinguish fibroadenomas from cysts Core-Needle Biopsy: Provides definitive diagnosis Treatment Conservative Management: Watchful waiting, regular monitoring (Option B) Surgical Excision: For larger fibroadenomas, those causing symptoms, or uncertain diagnosis Giant Fibroadenomas: Over 5 cm, may require excision through submammary incision (Option C) Prognosis Benign , do not increase risk of breast cancer Growth can vary, influenced by hormonal changes Recurrence is uncommon Relationship to ANDI Categorised according to ANDI as: Normal: Small fibroadenomas ( ≤ 1 cm) Disorder: Larger fibroadenomas ( ≤ 3 cm) Disease: Giant fibroadenomas (>3 cm), multiple fibroadenomas Cyst; surgical excision (Option A): Fibroadenomas are solid, not fluid-filled like cysts. Inflammatory carcinoma; urgent biopsy and treatment (Option D): Inflammatory carcinoma presents usually with rapid onset and extensive skin involvement. Reference: Sabiston Textbook of Surgery, 21st Edition, Pages 816,817, 826 Bailey & Love's Short Practice of Surgery, 28th Edition, Page 922 Schwartz's Principles of Surgery, 11th Edition, Pages 551-554",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 8,
      "question": "Which of the following statements regarding phyllodes tumor are correct? Statements: Tumors of mixed connective tissue and epithelium Classified as benign, intermediate, and malignant Discrete structure with cystic spaces in USG Excisional biopsy is the definitive diagnostic method",
      "options": {
        "A": "1,3",
        "B": "4",
        "C": "3,4",
        "D": "1,2,3,4"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) 1,2,3,4 Explanation: All 4 statements are correct Phyllodes tumor: Characteristic Details Description Tumors of mixed connective tissue and epithelium Classification Benign Phyllodes Tumors Intermediate (Borderline) Phyllodes Tumors Malignant Phyllodes Tumors Histological Features Benign: Similar to fibroadenomas with whorled stroma and leaf-like structures Malignant: Atypical cells, increased cellularity, high mitotic count, and stromal overgrowth Clinical Presentation Benign tumors: Lobulated, firm masses of average size ~5 cm Malignant tumors: Rapid growth and larger size; can occur in older patients Imaging Mammography: Round densities with smooth borders, indistinguishable from fibroadenomas Ultrasound: Discrete structure with cystic spaces Diagnosis Core needle biopsy (CNB) preferred Excisional biopsy is definitive Treatment Benign: Local excision Intermediate: Excision with negative margins (at least 1 cm) Malignant: Complete surgical excision; total mastectomy if large; possible adjuvant radiation therapy if margins are concerning Recurrence Risk Especially within the first 2 years after excision Reference: Sabiston Textbook of Surgery, 21st Edition, Pages 831-832",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 9,
      "question": "A 55-year-old menopausal woman presents with a unilateral, scaly, and erythematous lesion on her nipple, initially resembling eczema but without itching (image given below). She was diagnosed with Paget’s disease of the nipple. Which of the following cancers is most commonly associated with Paget’s disease?",
      "options": {
        "A": "Invasive ductal carcinoma",
        "B": "Invasive lobular carcinoma",
        "C": "Ductal carcinoma in situ",
        "D": "Lobular carcinoma in situ"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: A) Invasive ductal carcinoma Explanation: Ductal carcinoma in situ is the most common carcinoma associated with Paget’s disease of the nipple. Intraductal carcinoma also known as DCIS. Paget’s disease of the nipple: Characteristic Details Nature of Disease Superficial manifestation of an intraductal carcinoma Symptoms Hard nodule just underneath the areola that later ulcerates and causes destruction of the nipple Histology Contains large, ovoid, clear Paget's cells with malignant features Incidence 2% of breast cancer cases Associated Carcinoma 90% is invasive ductal carcinoma Surgical Treatment Modified Radical Mastectomy (MRM) Characteristic Paget's Disease Eczema of Nipple Laterality Unilateral Bilateral Edges Distinct Indistinct Itching Absent Present Occurrence Seen in menopausal women Occurs during the time of lactation Vesicles Absent Present Nipple Condition Nipple is usually destroyed Nipple is usually intact Underlying Lump Usually present No underlying lump",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxsurgery/Endocrine_Surgery-Breast-Ii_Q9_q.jpg",
      "explanation_image": null,
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 10,
      "question": "A 65-year-old man presents with a hard, unilateral breast lump and nipple retraction. Clinical examination reveals skin dimpling and axillary lymphadenopathy. A biopsy confirms breast cancer. Which of the following is wrong about his diagnosis?",
      "options": {
        "A": "Associated with BRCA2 mutation",
        "B": "Most common in 3rd decade of life",
        "C": "Poorer prognosis compared to carcinoma breast in females",
        "D": "Infiltrating duct carcinoma is the most common type"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Most common in 4th decade of life Explanation: Male breast cancer is more common in the 60s than in the 40s Male breast cancer: Characteristic Details Incidence Less than 1% of breast cancer cases Mean Age 65 years Risk Factors BRCA2 gene mutation Radiation Excess estrogen Cirrhosis Klinefelter's syndrome Liver schistosomiasis Family history Testicular disease Infertility Obesity Common Type Infiltrating duct carcinoma (90%) , Ductal carcinoma in situ (10%) Clinical Features Unilateral hard breast lump Eccentric Nipple retraction and discharge Skin dimpling Axillary lymphadenopathy Investigations and Treatment Same as carcinoma of the female breast Prognosis Poorer prognosis compared to carcinoma breast in females Reference: SRB's Manual of Surgery, 6th Edition, Pages 551-552",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 11,
      "question": "A 25-year-old was diagnosed with invasive ductal carcinoma in her 5th week of gestation. Her axillary lymph node biopsy has come back positive. What is the most appropriate management along with modified radical mastectomy?",
      "options": {
        "A": "Termination of pregnancy",
        "B": "Chemotherapy",
        "C": "Radiation therapy",
        "D": "Termination of pregnancy and chemotherapy"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) Termination of pregnancy and chemotherapy Explanation: Breast cancer during pregnancy: Chest X-ray should be done with abdominal shield; MRI is the investigation of choice for primary breast tumor and metastatic work-up Termination of pregnancy may be required when distressing secondaries are present Management: 1st trimester 2nd trimester 3rd trimester Modified radical mastectomy Modified radical mastectomy Modified radical mastectomy Termination and chemotherapy if the axillary lymph node-positive Careful chemotherapy After delivery - chemotherapy (lactation is contraindicated) Reference: SRB's Manual of Surgery, 6th Edition, Page 552",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 12,
      "question": "A 45-year-old woman presents with a palpable mass in her left breast. On examination, the mass is 3 cm in diameter, and there is no evidence of skin or chest wall involvement. An ultrasound reveals a single enlarged axillary lymph node. Biopsy confirms invasive ductal carcinoma, ER/PR positive, HER2 negative, shows no distant metastasis. What is the most appropriate management approach?",
      "options": {
        "A": "Total mastectomy with sentinel lymph node biopsy (SLNB)",
        "B": "Breast-conserving surgery (BCS) with SLNB followed by radiotherapy (RT)",
        "C": "Neoadjuvant chemotherapy followed by mastectomy",
        "D": "BCS with axillary lymph node dissection (ALND) without radiotherapy"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Breast-conserving surgery (BCS) with SLNB followed by radiotherapy (RT) node, and M0 as there is no distant metastasis, placing it in Stage IIB. Management of Early Invasive Breast Cancer Stages Involved: I, IIA and IIB Breast Conservation Surgery (BCS): Preferred for suitable candidates to preserve breast tissue. Post-Operative Radiotherapy (RT): Given after BCS to prevent recurrence. Sentinel Lymph Node Biopsy (SLNB): Performed with BCS to assess lymph node involvement. BCS + SLNB + RT is the standard approach for most early-stage invasive breast cancer cases. If there are contraindications for breast conservation surgery: Simple Mastectomy (Total Mastectomy) + Axillary Lymph Node Sampling Reference: Bailey & Love's Short Practice of Surgery, 28th Edition, Pages 935-939. Schwartz's Principles of Surgery, 11th Edition, Pages 582-585. SRB's Manual of Surgery, 6th Edition, Pages 547,548.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 13,
      "question": "What is the primary purpose of a sentinel lymph node biopsy in the management of cancer, and how does it help guide treatment decisions?",
      "options": {
        "A": "To determine the exact stage of the cancer by identifying all affected lymph nodes.",
        "B": "To assess whether cancer has spread to the lymph nodes.",
        "C": "To completely remove all lymph nodes to prevent cancer recurrence.",
        "D": "To evaluate the effectiveness of chemotherapy before surgery."
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) To assess whether cancer has spread to the lymph nodes. Explanation: Sentinel Lymph Node Biopsy Sentinel lymph node/Gatekeeper node is the first lymph node which receives lymph directly from the tumour. It is used to assess whether cancer has spread to the lymph nodes which helps in staging the disease and deciding on the need for additional treatments. It is used in case of - Carcinoma breast Carcinoma penis Head and neck malignancies Carcinoma vulva Malignant melanoma Indications - Clinically non-palpable axillary lymph-node/clinically negative axilla. Main advantage - Avoids axillary lymph-node dissection. Techniques used in Sentinel lymph node biopsy Blue dye technique Radioactive tracer technique 1% Lymphazurin/isosulfan blue is injected around the tumour. It is injected inside areola around the nipple. The dye flows through the lymphatic system and stains the nodes. Technetium -99m labelled colloid is used. Gamma probe is used to detect radioactivity in sentinel lymph nodes. Tumor is localised and excised for biopsy Both blue dye and Radioactive colloid techniques are combined to enhance the accuracy of Sentinel lymph-node identification. Reference: Sabiston Textbook of Surgery, 21st Edition, Pages 840, 841 Biopsy image",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxsurgery/Endocrine_Surgery-Breast-Ii_Q13_exp.png",
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 14,
      "question": "Which of the following components is not evaluated in the Bloom-Richardson grading system?",
      "options": {
        "A": "Tubule formation",
        "B": "Nuclear pleomorphism",
        "C": "Mitotic count",
        "D": "Tumor size"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) Tumor size Explanation: The Bloom-Richardson grading system, also known as the Nottingham grading system, assigns points to three histological features of breast cancer. Each feature is scored from 1 to 3, with higher scores indicating more aggressive features. The total score determines the overall grade of the tumor. This grading system helps in assessing the aggressiveness of breast cancer and aids in determining the prognosis and treatment plan for patients. Histological Features and Scoring: Features Score Tubule Formation: Percentage of the tumor that forms normal duct structures Score 1 : >75% of tumor area forms tubules Score 2 : 10-75% of tumor area forms tubules Score 3 : <10% of tumor area forms tubules Nuclear Pleomorphism: Variation in size and shape of the tumor cell nuclei Score 1 : Small, uniform nuclei Score 2 : Moderate increase in size and variability Score 3 : Marked variation in size and shape, large and bizarre nuclei Mitotic Count: Number of mitoses per 10 high-power fields Score 1 : 0-9 mitoses per 10 high-power fields Score 2 : 10-19 mitoses per 10 high-power fields Score 3 : 20 or more mitoses per 10 high-power fields Total Score and Corresponding Grade: Grades Score Grade 1 : Well-differentiated 3-5 Grade 2 : Moderately differentiated 6-7 Grade 3 : Poorly differentiated 8-9 Reference: https://pubmed.ncbi.nlm.nih.gov/15920556/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 15,
      "question": "Which of the following statements about the TRAM flap is true? reconstruction.",
      "options": {
        "A": "The TRAM flap uses only skin and fat from the abdomen, preserving the abdominal muscle.",
        "B": "The TRAM flap relies on tissue from the back, including skin and muscle, for reconstruction.",
        "C": "The TRAM flap involves using tissue from the abdomen, including both skin and muscle, for breast",
        "D": "The TRAM flap uses tissue from the thigh, including skin and fat, to reconstruct the breast."
      },
      "correct_answer": "C",
      "explanation": "and muscle, for breast reconstruction. Correct Answer: C) The TRAM flap involves using tissue from the abdomen, including both skin and muscle, for breast reconstruction. Explanation: Breast Reconstruction Flaps Flaps Clinical Correlation Transverse Rectus Abdominis Muscle Flap (TRAM) Free flap involves using tissue from the abdomen, including both skin and muscle Most commonly used flap but not the best flap It is based on inferior epigastric vessels Disadvantage: causes weakness in infra umbilical region Deep Inferior Epigastric Artery Perforator flap (DIEP) Flap which uses skin and fat from lower abdomen, but spares abdominal muscles Best flap for breast reconstruction as there is no risk of hernia and muscle weakness Latissimus Dorsi Flap Flap which uses Latissimus dorsi muscle, skin and fat It is a type of subcutaneous flap based on thoracodorsal vessels.",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxsurgery/Endocrine_Surgery-Breast-Ii_Q15_exp.jpg",
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 16,
      "question": "A patient develops a painful, swollen area in the axillary region two weeks after mastectomy. What is the most likely diagnosis?",
      "options": {
        "A": "Seroma",
        "B": "Lymphedema",
        "C": "Hematoma",
        "D": "Axillary lymphadenopathy"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Seroma Explanation : Seroma Common complication following mastectomy, characterized by the accumulation of serous fluid in the surgical site, particularly in the axillary region. Seromas are more specifically associated with fluid accumulation after surgery. Complications of mastectomy Complications Explanations Lymphedema (Option B) Swelling caused by the accumulation of lymph fluid in the arm or chest wall due to the removal of lymph nodes.(After MRM and axillary dissection) Wound infection/Flap necrosis Postoperative infections where blackening of suture line is seen (flap necrosis), if necrosed site note removed, leads to wound infection Post-Mastectomy Pain Syndrome Chronic pain in the chest or upper arm due to nerve damage or scar tissue formation. Nerve Injuries Long thoracic nerve- injury leads to winging of scapula Thoracodorsal nerve Lymphangiosarcoma Stewart-treves syndrome - Cancerous growth in the lymphatic vessels, often associated with long-standing lymphedema. After an average of 10.5 years following MRM and radiotherapy, patient develops angiosarcoma Hematoma (Option C) : A hematoma is a collection of blood in the tissue and can cause swelling and discomfort. However, it usually presents sooner after surgery (within days) and may be associated with more severe pain. Axillary Lymphadenopathy (Option D) : Enlargement of the lymph nodes in the axilla can occur, but it usually indicates a reactive or malignant process rather than an immediate postoperative issue. It might present with a firm, discrete mass rather than diffuse swelling. Reference: Sabiston Textbook of Surgery, 21st Edition, Page 832 SRB's Manual of Surgery, 6th Edition, Pages 25 & 26 Complications",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 17,
      "question": "Match the following hormonal therapy drugs with their primary use: 1.Tamoxifen a. Pre-menopausal hormone receptor-positive breast cancer 2.Anastrozole b. Post-menopausal hormone receptor-positive breast cancer 3.Fulvestrant c. HER2-positive breast cancer 4.Trastuzumab d. Hormone receptor-positive metastatic breast cancer",
      "options": {
        "A": "1-a, 2-b, 3-d, 4-c",
        "B": "1-b, 2-c, 3-d, 4-a",
        "C": "1-a, 2,d, 3-b, 4-c",
        "D": "1-c, 2-a, 3-b, 4-d"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) 1-a, 2-b, 3-d, 4-c Explanation: Hormonal therapy for breast cancer Drug Given for Clinical Correlation Tamoxifen Pre-menopausal hormone receptor-positive breast cancer Selective estrogen receptor modulator (SERM) works by blocking estrogen receptors on breast cancer cells, which can slow or stop the growth of tumors that require estrogen to grow. Anastrozole Post-menopausal hormone receptor-positive breast cancer Aromatase inhibitors that reduce the production of estrogen in the body by blocking the enzyme aromatase, which converts androgens into estrogen in postmenopausal women. Fulvestrant Hormone receptor-positive metastatic breast cancer Estrogen receptor antagonists work by binding to estrogen receptors and degrading them, which helps to reduce the growth of estrogen-dependent cancer cells. Trastuzumab HER2-positive breast cancer Monoclonal antibodies that target the HER2 receptor inhibit the growth of cancer cells and can also recruit the body's immune system to destroy these cells. Reference: Bailey & Love's Short Practice of Surgery, 28th Edition, Pages 940, 941 Sabiston Textbook of Surgery, 21st Edition, Pages 848, 849",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 18,
      "question": "Which of the following types of breast carcinoma is most likely to respond best to radiation therapy?",
      "options": {
        "A": "Invasive ductal carcinoma",
        "B": "Inflammatory breast cancer",
        "C": "Ductal carcinoma in situ (DCIS)",
        "D": "Triple-negative breast cancer"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Ductal carcinoma in situ (DCIS) Explanation: Ductal carcinoma in situ (DCIS) is non-invasive, with cancer cells confined to the breast ducts. Radiation therapy is highly effective, especially after lumpectomy, significantly reducing recurrence risk. DCIS responds exceptionally well to radiation, making it the most responsive among these options. Radiotherapy: Indications: Breast-Conserving Surgery (BCS): To reduce local recurrence. Post-Mastectomy: For large tumors or positive lymph nodes. Locally Advanced Disease: To shrink tumors preoperatively. Metastatic Disease: For symptom relief. Positive Lymph Nodes: To reduce regional recurrence. High-Risk Features: To lower recurrence risk. Ductal Carcinoma In Situ (DCIS): Responds exceptionally well to radiation and prevents local recurrence post-surgery. Types: External Beam Radiotherapy (EBRT): Targets the tumor precisely; used post-surgery, for regional lymph node involvement, and in both early and advanced cases. Brachytherapy: Radioactive sources placed directly in or near the tumor; used as a boost after lumpectomy or for partial breast irradiation. Intraoperative Radiotherapy (IORT): Delivered during surgery to the tumor bed; minimizes recurrence risk immediately post-surgery. Hypofractionated Radiotherapy: Higher doses over a shorter period; used for early-stage cancer to improve convenience and maintain efficacy. Invasive ductal carcinoma (IDC) (Option A) is the most common type of breast cancer. It can spread beyond the breast, requiring multimodal treatment including surgery, chemotherapy, and radiation therapy. Inflammatory breast cancer (IBC) (Option B): Treatment includes chemotherapy, surgery, and radiation therapy. Triple-negative breast cancer (TNBC) (Option D) lacks estrogen, progesterone receptors, and HER2 protein, limiting treatment options. It often requires chemotherapy and may include radiation for local control post-surgery. However, due to its aggressive nature and lack of specific targets, TNBC’s response to radiation alone is not as pronounced as DCIS. Reference: Bailey & Love's Short Practice of Surgery, 28th Edition, Pages 939,940. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161063/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 19,
      "question": "A 55-year-old woman with Stage IV HER2-positive metastatic breast cancer presents with fungation of the breast, multiple metastases to the liver and bones. Which of the following treatment strategies is most appropriate for her condition?",
      "options": {
        "A": "Trastuzumab + Chemotherapy + Palliative mastectomy",
        "B": "Tamoxifen + Radiation Therapy + Bone-targeted therapy",
        "C": "Hormonal Therapy alone",
        "D": "Surgical Resection of Metastases + Radiotherapy"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Trastuzumab + Chemotherapy + Palliative mastectomy Explanation: For Stage IV HER2-positive metastatic breast cancer, treatment involves systemic therapies such as Trastuzumab combined with chemotherapy (e.g., taxanes or capecitabine) to inhibit the HER2 protein and manage systemic disease, along with palliative mastectomy to alleviate severe symptoms and improve quality of life. Management of Stage IV HER2-Positive Metastatic Breast Cancer Type Description Treatment Systemic Therapy Targeted Therapy: Specific for HER2-positive cancers Trastuzumab, Pertuzumab, Lapatinib Chemotherapy: Addresses systemic disease Taxanes, Anthracyclines, Capecitabine Hormonal Therapy: For hormone receptor-positive cases (not standalone for HER2-positive) Tamoxifen, Aromatase Inhibitors (if combined) Local Therapy Palliative Surgery: Relieves significant symptoms from primary tumor growth Mastectomy Radiotherapy: Controls localized symptoms, especially bone metastases _ Bone-targeted Therapy Manages bone metastases and reduces skeletal-related events Bisphosphonates, Denosumab Tamoxifen + Radiation Therapy + Bone-targeted Therapy (Option B) is inappropriate for HER2-positive breast cancer as tamoxifen is used for hormone receptor-positive tumors, and radiation alone does not address systemic disease. Hormonal Therapy Alone (Option C) is not effective for HER2-positive cancers, which are resistant to hormonal treatments. Surgical Resection of Metastases + Radiotherapy (Option D) is not typically indicated in Stage IV disease due to the palliative rather than curative intent. Radiotherapy may be used for symptom control, not as a sole treatment. Reference: Bailey & Love's Short Practice of Surgery, 28th Edition, Page 941. Schwartz's Principles of Surgery, 11th Edition, Page 587. SRB's Manual of Surgery, 6th Edition, Pages 549, 550.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    },
    {
      "q_no": 20,
      "question": "A 52-year-old woman presents with Stage III B breast cancer. Her diagnostic workup includes imaging studies and biopsy, revealing a locally advanced tumor with involvement of regional lymph nodes. The tumor is hormone receptor-positive and HER2-positive. What would be the most appropriate management approach for this patient?",
      "options": {
        "A": "Neoadjuvant chemotherapy followed by modified radical mastectomy and adjuvant radiotherapy",
        "B": "Immediate modified radical mastectomy followed by adjuvant chemotherapy and endocrine therapy",
        "C": "Primary endocrine therapy followed by adjuvant chemotherapy and radiotherapy",
        "D": "Neoadjuvant chemotherapy followed by lumpectomy and adjuvant radiotherapy"
      },
      "correct_answer": "A",
      "explanation": "adjuvant radiotherapy Correct Answer: A) Neoadjuvant chemotherapy followed by modified radical mastectomy and adjuvant radiotherapy Explanation: Management of Locally Advanced Breast Cancer (LABC) Stages Involved: Stage IIIA , IIIB and IIIC Neoadjuvant Chemotherapy (NACT): Administered before surgery to shrink the tumor, making it operable and allowing for breast conservation if possible. This also helps assess the tumor's response to treatment. Modified Radical Mastectomy (MRM) : Performed after neoadjuvant chemotherapy to remove the breast tissue and axillary lymph nodes. The surgery aims to achieve local control and address regional disease. Post-Surgery Radiotherapy (RT): Administered after MRM to reduce the risk of local recurrence and ensure any remaining microscopic disease is treated. NACT + MRM + RT is the standard approach for LABC to ensure comprehensive treatment. This sequence allows for effective tumor reduction, surgical resection, and post-operative control to prevent a recurrence. Reference: Bailey & Love's Short Practice of Surgery, 28th Edition, Pages 939-941. Schwartz's Principles of Surgery, 11th Edition, Pages 582-585. SRB's Manual of Surgery, 6th Edition, Pages 548, 549.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrine Surgery-Breast-Ii"
    }
  ]
}
